Skip to main content
. 2020 Jul 9;14:1753466620938553. doi: 10.1177/1753466620938553

Key points (3).

• NTRK inhibition (larotrectinib) has a high added therapeutic value and constitutes an unsatisfied medical therapeutic need.
• There are no studies that have evaluated (locally or internationally) the cost-effectiveness of larotrectinib. However, the clear clinical benefit for diverse rare tumors that carry the NTRK1–3 fusion gene constitutes a balanced strategy for different sanitary models on a global scale.